GLPG’s FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track

Today’s Daily Dose brings you news about the outcome of Data and Safety Monitoring Board’ interim analysis of ARCA biopharma’s GENETIC-AF trial; stock offerings of Dynavax and Esperion; results of Galapagos’ idiopathic pulmonary fibrosis study; Heron’s progress in phase III program of HTX-011 and Sangamo’s encouraging financial results.

Read on…

The Data and Safety Monitoring Board has completed the pre-specified interim analysis of ARCA biopharma Inc.’s (ABIO) GENETIC-AF trial. The DSMB has asked the Company to continue the trial with no changes.

GENETIC-AF is a phase 2B/3 double-blind, clinical superiority trial comparing the safety and efficacy of ARCA bio’s investigational drug Gencaro to an approved drug TOPROL-XL for the treatment and prevention of recurrent atrial fibrillation or flutter (AF/AFL) in heart failure patients with reduced left ventricular ejection fraction (HFrEF).

The Company expects reporting top-line results from the GENETIC-AF trial in the first quarter of next year.

ABIO closed Wednesday’s trading at $1.70, down 8.11%. In after-hours, the stock gained 8.82% and was at $1.85.

Dynavax Technologies Corp. (DVAX) has offered to sell 5 million shares of its common stock to the public at a price of $15.00 each.

The Company has granted the underwriters a 30-day option to purchase at the public offering price up to an aggregate of 750,000 additional shares of its common stock to cover over-allotments, if any. The gross proceeds to Dynavax from this offering are expected to be approximately $75 million.

The offering is expected to close on or about August 15, 2017, subject to customary closing conditions.

The Company’s New Drug Application for Heplisav-B, an experimental hepatitis B vaccine, is under FDA review, with a decision date set for November 10, 2017.

DVAX closed Wednesday’s trading at $17.20, down 7.77%.

Esperion Therapeutics Inc. (ESPR) has offered to sell 3.10 million shares of its common stock to the public at a price of $49.00 per share.

The underwriters have a 30-day option to purchase up to an additional 465,000 shares of its common stock. The gross proceeds from this offering to Esperion are expected to be $151.9 million.

The offering is expected to close on or about August 15, 2017, subject to customary closing conditions.

Esperion shares touched an all-time intraday high of $57.38 on Aug.8, 2017, following positive top-line results from its phase II study evaluating the LDL-C lowering efficacy and safety of the Bempedoic…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *